Predictive potential of pan-immune-inflammation value / hemoglobin index as biomarker for osteoradionecrosis risk in locally advanced nasopharyngeal carcinomas

Basit Öğe Kaydı
dc.authoridYilmaz, Busra/0000-0003-0633-5648
dc.contributor.authorYilmaz, Busra
dc.contributor.authorSomay, Efsun
dc.contributor.authorTopkan, Erkan
dc.contributor.authorPehlivan, Berrin
dc.contributor.authorBesen, Ali Ayberk
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorSelek, Ugur
dc.date.accessioned2024-05-19T14:42:15Z
dc.date.available2024-05-19T14:42:15Z
dc.date.issued2024
dc.departmentİstinye Üniversitesien_US
dc.description.abstractObjective: We aimed to investigate whether the Pan-Immune-Inflammation-Value/Hemoglobin (PIV/Hb) index could predict the risk of osteoradionecrosis (ORN) in patients receiving concurrent chemoradiotherapy (CCRT) for locally advanced nasopharyngeal cancer (LA-NPC). Materials and methods: This retrospective analysis included LA-NPC patients who underwent CCRT and preCCRT oral exams at our institution's Departments of Radiation Oncology and Dentistry between January 2010 and December 2022. The relationship between ORN rates and PIV-Hb levels was explored using receiver operating characteristic curve analysis. The primary objective was to establish a correlation between pre-CCRT PIV-Hb levels and ORN rates, while the secondary objective was to identify other risk factors for ORN. Results: Of 249 eligible patients, 21 (8.4 %) were diagnosed with ORN. The optimal pre-CCRT PIV/Hb cutoff was 73.8, which divided patients into two subgroups with distinctive ORN risk estimates: Group 1: PIV/ Hb < 73.8 (N = 206), and Group 2: PIV/Hb >= 73.8 (N = 43). The results of the comparative analysis indicated that the cohort with PIV/Hb >= 73.8 exhibited substantially higher rates of ORN than the PIV/Hb < 73.8 cohort (44.2 % vs. 1.0 %; P < 0.001). The multivariate logistic regression analysis indicated that the pretreatment PIV/ Hb >= 73.8 was independently associated with higher ORN rates (P < 0.001). Conclusion: The results of our current investigation indicate that higher levels of pretreatment PIV/Hb were associated with a significant independent increase in ORN rates in LA-NPC patients who received CCRT. (c) 2024 Elsevier Masson SAS. All rights reserved.en_US
dc.identifier.doi10.1016/j.jormas.2024.101786
dc.identifier.issn2468-8509
dc.identifier.issn2468-7855
dc.identifier.issue6en_US
dc.identifier.pmid38286220en_US
dc.identifier.scopus2-s2.0-85183988057en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org10.1016/j.jormas.2024.101786
dc.identifier.urihttps://hdl.handle.net/20.500.12713/5219
dc.identifier.volume125en_US
dc.identifier.wosWOS:001177738500001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Stomatology Oral and Maxillofacial Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240519_kaen_US
dc.subjectHead And Neck Canceren_US
dc.subjectOsteoradionecrosisen_US
dc.subjectBiomarkersen_US
dc.subjectPan-Immune-Inflammation-Valueen_US
dc.subjectHemoglobinen_US
dc.subjectNasopharyngeal Canceren_US
dc.subjectConcurrent Chemoradiotherapyen_US
dc.titlePredictive potential of pan-immune-inflammation value / hemoglobin index as biomarker for osteoradionecrosis risk in locally advanced nasopharyngeal carcinomasen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu